The Institute for Cell, Gene and Immunotherapy (ICGI) is a translational research institute that develops novel cell, gene and immunotherapies for a range of diseases through collaboration between clinical departments within the Medical School and basic research laboratories in centers, institutes and other colleges at the University of Minnesota.
In response to the COVID19 pandemic: ICGI leadership will make available expertise and key resources to aid faculty in the development of investigator-initiated clinical trials and investigational new drug (IND) applications, prioritizing applications in anticipation of federal funding opportunities.
Cell, Gene or Immunotherapy proposals aimed at:
- Prevention of SARS-CoV-2 virus infection or proliferation
- Prevention and treatment of COVID-19 mediated complications